Skip to main content
Top

31-10-2023 | Urothelial Cancer | Expert Interview | Article

ESMO 2023: Advances in urothelial cancer

print
PRINT
insite
SEARCH
Host:
Dr. Shreeya Nanda

Dr. Enrique Grande discusses the findings of the EV-302 trial of enfortumab vedotin plus pembrolizumab and the CheckMate 901 trial of nivolumab plus chemotherapy, both conducted in the advanced urothelial cancer setting.

Speaker

  • Dr. Enrique Grande 
    MD Anderson Cancer Center Madrid, Spain
print
PRINT

Related topics

Related content

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine